BUZZ-Kodiak Sciences drops after stock deal unveil

Reuters12-16 06:00
BUZZ-Kodiak Sciences drops after stock deal unveil

** Shares of eye-drug developer Kodiak Sciences KOD.O down 4.4% in extended trading to $22 as it looks to raise equity

** Palo Alto, California-based precommercial biotech commences 6 mln share offering

** JP Morgan, Jefferies, Evercore and UBS are joint bookrunners

** KOD shares fell for 5th-straight session on Mon, finishing down 3.3% at $23.02. But the stock has soared more than six-fold over the past six months

** With ~53 mln shares outstanding, co has $1.2 bln market cap

** Of 8 analysts covering KOD, recommendation breakdown is 5 "strong buy" or "buy", 2 "hold" and 1"sell"; median PT is $24, current LSEG data reflects

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment